A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2014-06-03
Target enrollment:
Participant gender:
Summary
This open-label single arm study will assess the efficacy, safety and tolerability of
Vemurafenib in previously treated patients with metastatic melanoma. Patients will receive
oral Vemurafenib [RG7204; PLEXXIKON: PLX4032] at a dose of 960 mg b.i.d. continuously until
disease progression or withdrawal from study and will be assessed at regular intervals for
tumour response and tolerability. Target sample size is <100 patients.